AstraZeneca Atacand comparative efficacy
FDA's Cardiovascular & Renal Drugs Advisory Committee will review Atacand (candesartan) for proposed comparative efficacy claim to Merck's Cozaar (losartan) in treatment of hypertension on July 18. The sNDA (20-338/S-015) is based on AstraZeneca's CLAIM studies conducted in 1,200 patients. The meeting will take place at the Holiday Inn-Bethesda, Md., beginning at 8 a.m. [To sign up for a 1webcast, go to FDAAdvisoryCommittee.com]....
You may also be interested in...
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.
Inovio Pharmaceuticals has reported promising initial data from its first Phase III study of its electrical current-driven DNA plasmid-based immunotherapy, VGX-3100, in virus-associated cervical dysplasia; it is heading a small group of companies evaluating novel therapies in the condition, which often advances to cancer.
In the month ahead, a key ANDA approval could come for Viatris, while additional competition to Gilead Sciences’ Truvada for PrEP is on the way in the US following Teva and Amneal’s launches.